VX-950-TiDP24-C216: A Safety and Efficacy Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

• Sustained Virologic Response (SVR) in Prior Relapsers [ Time Frame: Week 72 ] [ Designated as safety issue: No ]
  The primary parameter was the proportion of subjects in each treatment group achieving sustained virologic response, defined as having undetectable plasma HCV RNA levels 24 weeks after the last planned dose of study drug (SVR24planned).
• Sustained Virologic Response (SVR) in Prior Non-responders [ Time Frame: Week 72 ] [ Designated as safety issue: No ]
  The primary parameter was the proportion of subjects in each treatment group achieving sustained virologic response, defined as having undetectable plasma HCV RNA levels 24 weeks after the last planned dose of study drug (SVR24planned).

The purpose of this study is to determine the safety, efficacy and tolerability of using two regimens of telaprevir (with and without delayed start) with standard treatment compared to standard treatment alone in participants with chronic, genotype 1, hepatitis C. The participants must have failed previous treatment with pegylated interferon (Peg-INF) and ribavirin (RBV).

This is a randomized, double-blind, placebo-controlled Phase III trial with telaprevir in patients with chronic Hepatitis C Virus (HCV), genotype 1, infection who failed prior treatment with standard treatment. Standard treatment is defined as treatment with Peg-INF and RBV. The trial is designed to compare the efficacy, safety, and tolerability of 2 regimens of telaprevir (with and without delayed start) combined with standard treatment versus standard treatment alone. The trial will consist of a screening period of approximately 4 weeks, a 48-week treatment period, and a 24-week follow-up period. Patients will be eligible to enroll in the trial if they (1) had an undetectable HCV Ribonucleic Acid (RNA) level at the end of a prior course of standard treatment but did not achieve a response (viral relapsers), or (2) never had an undetectable HCV RNA level during or at the end of a prior course of standard treatment (non-responders). Approximately 650 patients (350 prior relapsers and 300 prior non-responders) will be randomized in a 2:2:1 ratio to one of 3 treatment groups: Treatment group A will receive telaprevir with standard treatment for 12 weeks; followed by placebo with standard treatment for 4 weeks; followed by standard treatment for 32 weeks. Treatment group B will receive placebo with standard treatment for 4 weeks; followed by telaprevir with standard treatment for 12 weeks; followed by standard treatment for 32 weeks. Treatment group C will receive placebo with standard treatment for 16 weeks; followed by standard treatment for 32 weeks. In both telaprevir regimens (A and B), patients will receive 12 weeks of 750 mg of telaprevir every 8 hours along with 48 weeks of standard treatment. Telaprevir or placebo will be given by mouth at a dose of 750 mg every 8 hours for 16 weeks. Peg-INF will be given as an injection under the skin at a dose of 180 mcg once every week for 48 weeks. RBV will be given by mouth at a dose of either 1000 or 1200 mg (depending on your body weight) two times per day for 48 weeks.

• Drug: Placebo/ Standard Treatment (ST)/ Telaprevir
  Placebo + ST (Standard Treatment =180 µg injection Peg IFNa2A/ 1000-1200 mg twice daily Ribavirin) for 4 wks, then Telaprevir 750 mg every 8h + ST for 12 wks, then ST for 32 wks
• Drug: Placebo/ Standard Treatment (ST)
  Placebo + ST (Standard Treatment =180 µg injection Peg IFNa2A/ 1000-1200 mg twice daily Ribavirin) for 16 wks, then ST for 32 wks
• Drug: Telaprevir/Standard Treatment (ST)/Placebo
  Telaprevir 750 mg every 8h + ST (Standard Treatment =180 µg injection Peg IFNa2A/ 1000-1200 mg twice daily Ribavirin) for 12 wks, then Placebo + ST for 4 wks, then ST for 32 wks

• Experimental: 001
  Telaprevir/Standard Treatment (ST)/Placebo Telaprevir 750 mg every 8h + ST (Standard Treatment =180 µg injection Peg IFNa2A/ 1000-1200 mg twice daily Ribavirin) for 12 wks then Placebo + ST for 4 wks then ST for 32 wks
  Intervention: Drug: Telaprevir/Standard Treatment (ST)/Placebo
• Experimental: 002
  Placebo/ Standard Treatment (ST)/ Telaprevir Placebo + ST (Standard Treatment =180 µg injection Peg IFNa2A/ 1000-1200 mg twice daily Ribavirin) for 4 wks then Telaprevir 750 mg every 8h + ST for 12 wks then ST for 32 wks
  Intervention: Drug: Placebo/ Standard Treatment (ST)/ Telaprevir
• Experimental: 003
  Placebo/ Standard Treatment (ST) Placebo + ST (Standard Treatment =180 µg injection Peg IFNa2A/ 1000-1200 mg twice daily Ribavirin) for 16 wks then ST for 32 wks
  Intervention: Drug: Placebo/ Standard Treatment (ST)

Inclusion Criteria:

• Patient must have chronic hepatitis C infection (genotype 1) with HCV RNA level >= 1000 IU/mL
• Patient must have failed at least 1 prior course of Peg-IFN/RBV therapy (standard treatment)
• Patient must be willing to use 2 effective methods of birth control for up to 7 months after last dose of study medication

Exclusion Criteria:

• Patient is a previous non-responder that is classified as a viral breakthrough case
• Patient is infected with Hepatitis C virus, genotype 1, exhibiting more than one subtype
• Patient has Hepatitis C virus, genotype 1, and exhibits co-infection with any other genotype
• Evidence of decompensated liver disease
• Patient has condition that requires use of systemic corticosteroids